Pembrolizumab in heavily pretreated and refractory cutaneous T-cell lymphoma: A single-center study
Journal of the American Academy of Dermatology · 2026-08 · 95 (2) · 516-518
DOI: 10.1016/j.jaad.2026.04.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-08. Verfasst von Sara Khoshniyati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: srozati1@jhmi.edu.
Zitieren
APA
Khoshniyati, S., Bui, T., Sterling, C. H., & Rozati, S. (2026). Pembrolizumab in heavily pretreated and refractory cutaneous T-cell lymphoma: A single-center study. Journal of the American Academy of Dermatology, 95(2), 516-518. https://doi.org/10.1016/j.jaad.2026.04.014
Vancouver
Khoshniyati S, Bui T, Sterling CH, Rozati S. Pembrolizumab in heavily pretreated and refractory cutaneous T-cell lymphoma: A single-center study. Journal of the American Academy of Dermatology. 2026;95(2):516-518. doi:10.1016/j.jaad.2026.04.014
BibTeX
@article{Khoshniyati2026,
author = {Khoshniyati, Sara and Bui, Toan and Sterling, Cole H and Rozati, Sima},
title = {Pembrolizumab in heavily pretreated and refractory cutaneous T-cell lymphoma: A single-center study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {2},
pages = {516--518},
doi = {10.1016/j.jaad.2026.04.014}
}
EUVIMED